ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,161Medicare Part D Prescriptions Filled, Including Refills

Rank: 374 out of 1844

$478K Total Retail Price of All Prescriptions

Rank: 397 out of 1844

343 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
61% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 343 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 343 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 6,985 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
SIMVASTATIN 363 333 1 3
LEVOTHYROXINE SODIUM 280 266 2 1
LISINOPRIL 231 192 3 4
AMLODIPINE BESYLATE 218 211 4 6
OMEPRAZOLE 188 152 5 5
FUROSEMIDE 164 148 6 7
HYDROCHLOROTHIAZIDE 159 143 7 9
POLYETHYLENE GLYCOL 3350 159 155 7 39
CITALOPRAM HBR 152 144 9 19
WARFARIN SODIUM 144 125 10 13
METFORMIN HCL 139 130 11 8
SERTRALINE HCL 129 94 12 21
HYDROCODONE-ACETAMINOPHEN 123 74 S3 13 2
TRAMADOL HCL 118 106 14 18
POTASSIUM CHLORIDE 109 106 15 16
ADVAIR DISKUS 102 101 16 51
RANITIDINE HCL 100 75 17 38
DONEPEZIL HCL 100 100 17 26
ATENOLOL-CHLORTHALIDONE 98 92 19 156
METOPROLOL SUCCINATE 90 85 20 14
METOPROLOL TARTRATE 88 75 21 11
ISOSORBIDE MONONITRATE ER 85 81 22 59
ATENOLOL 84 81 23 17
GABAPENTIN 82 61 24 15
CARBIDOPA-LEVODOPA 76 76 25 86
ATORVASTATIN CALCIUM 73 73 26 12
MIRTAZAPINE 71 58 27 49
ZOLPIDEM TARTRATE 71 48 27 23
LISINOPRIL-HYDROCHLOROTHIAZIDE 67 58 29 20
QUETIAPINE FUMARATE 67 55 29 82
TAMSULOSIN HCL 66 66 31 27
RISPERIDONE 63 41 32 65
ALLOPURINOL 63 63 32 29
EXELON 62 62 34 112
MELOXICAM 62 46 34 28
AMITRIPTYLINE HCL 61 37 R 36 72
PREDNISONE 60 52 37 40
DIGOXIN 58 58 38 67
KLOR-CON M20 55 55 39 54
CLOPIDOGREL 54 54 40 34
COMBIVENT 53 43 41 131
AMPHETAMINE SALT COMBO 52 0 S2 42 255
NAMENDA 51 51 43 33
OXYBUTYNIN CHLORIDE ER 51 44 43 126
METHADONE HCL 50 0 S2 45 133
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 26, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.